ERBA Diagnostics, Inc. (fka ERBA)

[Camaro1093]

IVAX Diagnostics Increases Product Line Through Distribution Agreement with
Biomerica

Adds Unique Rapid Point-of-Care Tests and 33 New ELISA Test Kits to be Sold by
Diamedix in the U.S. and Delta Biologicals in Global Markets

MIAMI & IRVINE, Calif., Apr 13, 2010 (BUSINESS WIRE) -- IVAX Diagnostics, Inc.
(IVD), a fully integrated in vitro diagnostics company, and Biomerica, Inc.
(BMRA), a global biomedical company, have signed a two-year agreement for the
distribution of Biomerica's products in the U.S. and globally, with certain
country and product exclusions.

The agreement provides IVAX Diagnostics the rights for its Diamedix Corporation
and Delta Biologicals S.r.l. subsidiaries to distribute Biomerica's suite of
products which includes 33 ELISA (Enzyme-Linked Immunosorbent Assay) test kits in
the areas of diabetes, gastrointestinal disease and bone/mineral disorders, and
more than 26 Rapid Point-of-Care tests. The products will be marketed under the
Biomerica name, or, if certain initial sales levels are achieved, under the
Diamedix brand in the U.S. and Delta Biologicals brand internationally.

Dr. Charles Struby, CEO and President of IVAX Diagnostics, said, "This agreement
with Biomerica is expected to not only broaden and enhance our ELISA suite of
products by adding GI, diabetes and bone/mineral testing products to our line of
autoimmune test kits, but also expand our entry into the Rapid Point-of-Care
testing market, a global market that is estimated to be $10.3 billion. We expect
Biomerica's products to significantly enhance our ability to offer unique and
innovative tests to the approximately 600 installed Mago(R) instruments that are
being used by our customers. This agreement is another step toward our goal of
expanding our innovative diagnostics products, and increasing our presence in
both the U.S. and international markets. We are pleased to be working with
Biomerica and bringing their novel tests to the marketplace."

Zackary Irani, CEO of Biomerica, said, "IVAX Diagnostics' customer base of nearly
600 installed Mago(R) instruments offers both our companies a significant
opportunity to increase sales. As our tests complement those already sold by
Diamedix and Delta Biologicals, we believe their experienced sales forces and
ability to reach global markets, will produce positive results."

About Biomerica , Inc.

Biomerica, Inc. (http://www.biomerica.com) is a global biomedical company that
develops, manufactures and markets advanced diagnostic products used at the
point-of-care (in home and in physicians' offices ) and in hospital/clinical
laboratories for the early detection of medical conditions and diseases. The
Company's products are designed to enhance the health and well being of people,
while reducing total healthcare costs. Biomerica primarily focuses on products
for diabetes, gastrointestinal disease and esoteric testing.

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc. (http://www.ivaxdiagnostics.com), headquartered in Miami,
Florida, is a fully integrated in vitro diagnostics company that develops,
manufactures and distributes in the United States and internationally,
proprietary diagnostic reagents, test kits and instrumentation, primarily for
autoimmune and infectious diseases, through its three subsidiaries: Diamedix
Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc.

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press
release are forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect
the business and prospects of IVAX Diagnostics, Inc., including, without
limitation: the risks and uncertainties associated with IVAX Diagnostics'
agreement with Biomerica, including, without limitation, that anticipated levels
of sales may not be achieved under the agreement, that the agreement may not be
able to expand the product lines and product markets in which IVAX Diagnostics
currently operates and expects to operate in the future, that the agreement may
not assist IVAX Diagnostics in its goal of increasing its product lines and
expanding its reach in the U.S. and in international markets, and that the
agreement may not provide IVAX Diagnostics with, or otherwise allow IVAX
Diagnostics to achieve, its intended results, whether business, financial or
otherwise; and other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements. In addition to
the risks and uncertainties set forth above, investors should consider the
economic, competitive, governmental, technological and other risks and
uncertainties discussed in IVAX Diagnostics' filings with the Securities and
Exchange Commission, including, without limitation, the risks and uncertainties
discussed under the heading "Risk Factors" in such filings.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for
forward-looking statements. Certain information included in this press release
(as well as information included in oral statements or other written statements
made or to be made by Biomerica contains statements that are forward-looking;
such as statements relating to intended launch dates, sales potential,
significant benefits, market size, growth of business, favorable positions,
expansion, expected orders, leading market positions, anticipated future revenues
or production volume of the Company, success of product and new product
offerings. Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results in the future,
and accordingly, such results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica. The potential risks
and uncertainties include, among others, fluctuations in the Company's operating
results due to its business model and expansion plans, downturns in international
and or national economies, the Company's ability to raise additional capital, the
competitive environment in which the Company will be competing, and the Company's
dependence on strategic relationships. The Company is under no obligation to
update any forward-looking statements after the date of this release.

SOURCE: IVAX Diagnostics, Inc.

Company Contact:
IVAX Diagnostics
Dr. Charles R. Struby, CEO & President, 305-324-2300
or
Biomerica, Inc.
Zackary Irani, CEO, 949-645-2111
or
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Linda Decker, Vice President
212-564-4700


Copyright Business Wire 2010